




Searching News Database: XenoPort
HSMN NewsFeed - 24 Jul 2018
Soligenix Announces Appointment of Mark Pearson to its Board of Directors
Soligenix Announces Appointment of Mark Pearson to its Board of Directors
HSMN NewsFeed - 17 Feb 2017
AcelRx Pharmaceuticals Appoints Vincent J. Angotti Chief Executive Officer
AcelRx Pharmaceuticals Appoints Vincent J. Angotti Chief Executive Officer
HSMN NewsFeed - 18 Aug 2015
Radius Health Announced That it Has Appointed Catherine Friedman to the Board of Directors
Radius Health Announced That it Has Appointed Catherine Friedman to the Board of Directors
HSMN NewsFeed - 27 Mar 2014
Nora Therapeutics Expands Board of Directors with Appointment of Dennis M. Fenton
Nora Therapeutics Expands Board of Directors with Appointment of Dennis M. Fenton
HSMN NewsFeed - 7 Jun 2012
GSK and XenoPort Receive FDA Approval for Horizant(R) for Postherpetic Neuralgia
GSK and XenoPort Receive FDA Approval for Horizant(R) for Postherpetic Neuralgia
HSMN NewsFeed - 18 Jan 2012
Astellas and XenoPort Announce Approval of Regnite(R) Tablets for Restless Legs Syndrome in Japan
Astellas and XenoPort Announce Approval of Regnite(R) Tablets for Restless Legs Syndrome in Japan
HSMN NewsFeed - 4 Apr 2011
Anacor Pharmaceuticals Appoints William J. Rieflin to Its Board of Directors
Anacor Pharmaceuticals Appoints William J. Rieflin to Its Board of Directors
HSMN NewsFeed - 24 Jan 2011
Genelux Corporation Expands Board of Directors, Appointing Dennis Fenton, Former Amgen Executive
Genelux Corporation Expands Board of Directors, Appointing Dennis Fenton, Former Amgen Executive
HSMN NewsFeed - 5 Oct 2010
NGM Biopharmaceuticals Names William J. Rieflin Chief Executive Officer and Director
NGM Biopharmaceuticals Names William J. Rieflin Chief Executive Officer and Director
HSMN NewsFeed - 9 Jan 2009
GSK and XenoPort Resubmit New Drug Application for Solzira(TM) in Restless Legs Syndrome
GSK and XenoPort Resubmit New Drug Application for Solzira(TM) in Restless Legs Syndrome
HSMN NewsFeed - 16 Oct 2007
Cortex Names Pierre V. Tran, MD, MMM, Chief Medical Officer and Vice President of Clinical Development
Cortex Names Pierre V. Tran, MD, MMM, Chief Medical Officer and Vice President of Clinical Development
HSMN NewsFeed - 25 Apr 2007
XenoPort Reports Positive Top-Line Phase 3 Trial Results of XP13512 in Restless Legs Syndrome
XenoPort Reports Positive Top-Line Phase 3 Trial Results of XP13512 in Restless Legs Syndrome
HSMN NewsFeed - 8 Feb 2007
GlaxoSmithKline and XenoPort Announce Agreement on Late-Stage Compound for RLS and Neuropathic Pain
GlaxoSmithKline and XenoPort Announce Agreement on Late-Stage Compound for RLS and Neuropathic Pain
HSMN NewsFeed - 14 Mar 2006
XenoPort Initiates Phase 3 Clinical Program for XP13512 as a Treatment for Restless Legs Syndrome
XenoPort Initiates Phase 3 Clinical Program for XP13512 as a Treatment for Restless Legs Syndrome
Additional items found! 11

Members Archive contains
11 additional stories matching:
XenoPort
(Password required)
XenoPort
(Password required)